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IBRITUMOMAB TIUXETAN (ZEVALIN) IN THE CONDITIONING REGIMEN
FOR AUTOLOGOUS AND REDUCED-INTENSITY ALLOGENEIC STEM-
CELL TRANSPLANTATION (SCT) IN PATIENTS WITH CHEMO-REFRAC-
TORY NON-HODGKIN’S LYMPHOMA
Shimoni, A.1, Zwass, T.1, Oksman, Y.1, Hardan, I.1, Shem-Tov, N.,
Yerushalmi, R.1, Avigdor, A.1, Ben-Bassat, I.1, Nagler, A.1 Chaim
Sheba Medical Center, Tel-Hashomer, Israel.
High-dose chemotherapy and autologous SCT has an established
role in the treatment of patients (pts) with ﬁrst chemosensitive
relapse of aggressive lymphoma. However, autologous SCT has
only limited success when performed in refractory/progressive
stage, and the expected 1-year DFS in this setting is 20%.
Allogeneic SCT may offer some advantage by providing graft-
versus-lymphoma effect, but outcome is still poor in refractory
disease. This study was designed to explore the inclusion of Zevalin
in the conditioning regimens given prior to autologous and re-
duced-intensity allogeneic SCT (RIC) in pts with refractory lym-
phoma. The study included 24 pts, median age 56 years (range
35–66). Fifteen pts had autologous and 9 had RIC SCT (sibling-5,
unrelated-4). Histology was diffuse large cell (n 11), transformed
low-grade (n  9), mantle cell (n  3), and follicular lymphoma
(n  1). All pts had active lymphoma at SCT, either primary
refractory (n  9) or refractory relapse (n  15), and 14 had bulky
disease at SCT. The median number of prior therapies was 3
(range 1–6). Rituximab 250 mg/m2 followed by Zevalin 0.4
mCi/kg were given on day 14. Chemotherapy was started on day
6, and was standard BEAM prior to autologous SCT and the
combination of ﬂudarabine and intravenous busulfan (6.4 mg/kg)
or melphalan (140 mg/m2) prior to RIC. All pts engrafted. There
were no early infusion reactions associated with Zevalin. Fourteen
pts achieved CR , 4 achieved PR, and 6 are not evaluable (3 early
death, 3 too early after SCT). With a median follow-up of 8
months (range 1–16), 17 pts are alive and 7 have died with an
estimated 1-year survival of 62% (39–85), 68% after autologous
and 47% after allogeneic SCT (P  NS). The 1-year DFS is 46%
(18–73). So far, only 3 pts relapsed with a 1-year cumulative
incidence of only 24% (8–71). Three pts died of multi-organ
toxicities, 1 died of acute GVHD, and 2 of late infections. The
cumulative incidence of non-relapse mortality at day100 was 18%
(7–45), 13% after autologous and 30% after allogeneic SCT.
These rates are expected in heavily pretreated pts with refractory
lymphoma and there was no additional toxicity related to Zevalin.
In conclusion, the inclusion of Zevalin in the conditioning regi-
mens given prior to autologous and RIC allogeneic SCT may
reduce the risk of post SCT relapse and improve the poor outcome
of pts with refractory lymphoma given SCT with standard regi-
mens. This observation merits further study in larger comparative
studies.
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CHARACTERIZATION OF CMRF-56 ANTIBODY FOR ISOLATION OF
BLOOD DENDRITIC CELLS FOR MULTIPLE MYELOMA IMMUNOTHER-
APY
Munster, D.1, Rossetti, T.1, Prue, R.1, Vari, F.1, Hart, D.1 Mater
Medical Research Institute, Brisbane, Queensland, Australia.
The CMRF-56 antibody, which detects a blood dendritic cell
(BDC) marker, will be used for immunoselection of cells from
leukapheresis products for immunotherapy of multiple myeloma.
The development of the laboratory grade CMRF-56 to a product,
which can be used for clinical application, has involved careful
characterization of the antibody. We have discovered that the
immunoreactivity of this antibody is remarkably sensitive to both
the pH of the elution buffer and time of exposure. Exposure of
antibody to pH2.0 for greater than 10 minutes completely abol-
ishes activity after an initial rapid increase in potency, pH2.5
resulted in a gradual increase in antibody potency that peaks at
approximately 5 hours, whilst maximum potency is reached at 100
hours after exposure to pH3.0. As a result of this sensitivity to acid
exposure, the consistency between CMRF-56 batches could be
highly variable. To improve this, antibody elution conditions were
standardized by controlling the time of exposure of the antibody.
Immunoselection using CMRF-56 antibodies eluted at different
pH indicated that the pH2.5 elution resulted in CMRF-56 BDC
preparations of acceptable yield and purity while the pH 2.0 elu-
tion produced BDC preparations with unacceptably low purity due
to contaminating monocytes and B cells. We found that the degree
of CMRF-56 antibody aggregation correlates strongly with immu-
noreactivity, indicating the mechanism of antibody binding may be
enhanced by aggregation or dimerisation. It was also possible to
markedly increase the immunoreactivity of the puriﬁed monomeric
form of CMRF-56 by short-term exposure to acid. These studies
have resulted in the development of a bioprocess for production of
the murine biotinylated CMRF-56 antibody which is compatible
with large-scale synthesis required for clinical trials. The biopro-
cess incorporates components which remove contaminating DNA,
host cell proteins, virus and endotoxin.
341
IMMUNE CONSOLIDATION AFTER STEM CELL TRANSPLANT FOR
CD20 NONHODGKIN’S LYMPHOMA USING MULTIPLE INFUSIONS OF
AUTOLOGOUS ACTIVATED T CELLS (ATC) WITH ANTI-CD3 x ANTI-
CD20 BISPECIFIC ANTIBODY (CD20Bi) TO IMPROVE GRAFT-VS-LYM-
PHOMA EFFECTS
Lum, L.G.1,2, Davol, P.1, Colvin, G.1,2, Rathore, R.1,2, Abedi, M.1,2,
Palushock, E.1, Olson, A.1, Tarro, T.1, Quesenberry, P.1,2 1. Roger
Williams Hospital, Providence, RI; 2. Boston University, Boston, MA.
Relapse after autologous stem cell transplant (SCT) for high risk
in remission, refractory or relapsed non-Hodgkin’s lymphoma
(NHL) patients remain unacceptably high. In order to augment the
anti-lymphoma effect and decrease relapsed rates, we combine the
cytotoxicity mediated by anti-CD3 activated autologous T cells
(ATC) armed with a anti-CD3 x anti-CD20 bispeciﬁc antibody
(CD20Bi) that redirects ATC to kill CD20 targets with SCT
after high dose chemotherapy (HDC). Arming with CD20Bi con-
verts each T cell into a cytotoxic T lymphocyte directed at CD20
targets. Our phase I trial tests whether multiple infusions of armed
ATC given after HDC consisting of cyclophosphamide, thiotepa,
and carboplatin (CTC) as a preparative regimen followed by SCT
are safe. Furthermore, we will evaluate whether such infusions will
provide an anti-lymphoma effect to improve overall survival and
disease free survival after SCT for NHL. Beginning day 4, the
patients receive immune consolidation consisting of 3 infusions of
CD20Bi-armed ATC per week for 3 weeks and then 1 infusion per
week for 6 additional weeks. Dose levels for the phase I trial are 5,
10, 15, and 20  109 cells/infusion with total armed ATC doses
equaling 75, 150, 225, and 300  109 CD20Bi-armed ATC. Pa-
tients receive daily subcutaneous IL-2 (300,000 IU/m2/day) begin-
ning within 24 hours of the ﬁrst infusion and ending on the day of
the last infusion. One patient has completed the ﬁrst dose level.
The ﬁrst patient was a 58 year old man with relapsed diffuse, large
B-cell lymphoma. He was primed with G-CSF, leukapheresed for
CD34 enriched PBSC and lymphocytes. His CD34 enriched
PBSC were cryopreserved and his T cells were expanded with
anti-CD3 activation and IL-2. The infused armed ATC product
was 96% CD3, 44% CD4, 53% CD8, 81% CD4CD45/RO,
and 93% CD8CD45/RO. He received a SCT after CTC and
completed all 15 infusions at the ﬁrst dose-level (total of 75  109)
without any side-effects. He is 90 days after SCT and his restaging
is pending. The cytotoxicicity mediated by the patient’s ex vivo
expanded, armed ATC against the B9C cell line was considerably
higher than unarmed ATC. These early results suggest that large
numbers of armed autologous ATC can be infused after HDC and
SCT without major side effects. This strategy used in combination
with HDC and SCT may provide an unique opportunity to in-
crease the GVL effect without increasing toxicities after SCT for
hematologic malignancies.
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A COMPARISON OF MOLECULAR PROGNOSTIC TESTS IN MULTIPLE
MYELOMA
van den Berghe, J.1, Fesser, J.1, Wanda, H.1,2, Michael, V.1,2 1.
University of Saskatchewan, Saskatoon, SK, Canada; 2. Stem Cell
Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK,
Canada.
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Triaging multiple myeloma patients for stem cell transplantation
relies heavily on the identiﬁcation of high-risk prognostic factors.
Although a variety of molecular cytogenetic methods are widely
utilized, it is not clear which, if any, has a greater value than others.
In addition, identiﬁcation of the best test(s) would assist in con-
serving valuable resources, especially at smaller centers. We con-
ducted a comparative study on the bone marrow aspirates of 74
consecutive patients with Salmon-Durie Stage I, II, or III disease.
The majority (59/74) of patients were clinically in advanced stage
and planned to undergo therapy. On each patient, image analysis of
morphologically selected interphase plasmacytes was utilized to
ascertain the DNA ploidy level and karyotype analysis was at-
tempted on metaphases obtained following cell culture. Fluores-
cence in situ hybridization (FISH) for RB1 and TP53 was per-
formed in all cases with 	30% bone marrow plasmacytes. Neither
the detection of hypodiploidy or hyperdiploidy by image analysis
or the deletion of TP53 by FISH correlated with survival (P .871
and P  .792, respectively). Deletion of the RB1 locus was ob-
served in 27% of patients tested and tended to signiﬁcance (P 
.270). A karyotype was achieved in 43% of patients. An abnormal
karyotype was observed only in Stage III patients and was signiﬁ-
cantly linked to poor survival by Kaplan-Meier analysis (P  .002).
Evaluating a small cohort with a short observation period and using
the endpoint of death, highlights those tests most linked to ad-
vanced stage disease and identiﬁes those patients most likely to
beneﬁt from stem cell transplantation. A cost-effective algorithm is
suggested in which cytogenetic analysis is performed only on Stage
III patients and FISH for a 13q14 locus alone is performed in those
with 	30% bone marrow plasmacytes.
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OUTCOMES OF SALVAGE CHEMOTHERAPY AND AUTOLOGOUS TRANS-
PLANTATION FOR LARGE CELL TRANSFORMATION OF FOLLICULAR
LYMPHOMA—A COMPARISON OF OUTCOMES WITH RELAPSED/RE-
FRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Kuruvilla, J.1, Chen, C.1, Pintilie, M.2, Nagy, T.1, Keating, A.1,
Crump, M.1 1. University of Toronto Autologous Blood and Marrow
Transplant Program, Princess Margaret Hospital, Toronto, ON, Can-
ada; 2. Clinical Study Coordination, Princess Margaret Hospital, To-
ronto, ON, Canada.
Introduction: Recent data demonstrate that large cell transfor-
mation (TR) of follicular lymphoma (TRFL) has a different gene
expression proﬁle than diffuse large cell lymphoma (DL). Out-
comes of salvage chemotherapy and autologous stem cell trans-
plantation (ASCT) for TRFL are unclear. We compared the over-
all response rate (ORR) to salvage chemotherapy, progression-free
(PFS) and overall survival (OS) of TRFL patients (pts) to pts with
relapsed or refractory (RR) DL. Methods: We reviewed cases
between January 1995 and December 2004 and identiﬁed 56 pts
with biopsy proven DL that had arisen from Follicular Grade 1 or
2 lymphoma treated with chemotherapy with the intent to proceed
to ASCT. One hundred forty-three consecutive pts with RR-DL
who received salvage chemotherapy between January 1, 1999 and
December 31, 2004 served as a control. Pts received anthracycline
or platinum-based salvage therapy to assess chemotherapy sensi-
tivity; responders proceeded to PBSC mobilization and ASCT.
The intensive therapy regimen consisted of high-dose etoposide 60
mg/kg day 4 and melphalan 180 mg/m2 day 3 (with or without
1200 cGy TBI in 6 fractions) with PBSC infusion day 0. Results:
The median age at the initiation of salvage chemotherapy was 54
years (range 31–65) in the TRFL pts versus 53 (21–66) in the
RR-DLBCL pts (P  .31, Wilcoxon). The median time from
diagnosis of FL to diagnosis of TRFL was 4 years (range 0.6–23).
Advanced stage disease at TR was found in 78% of TRFL pts
versus 52% of RR-DLBCL pts (P  .0007 -square). The median
number of treatments for TRFL pts was 2 (range 0–8) while the
median number of prior treatments for RR-DLBCL was 1 (range
1–3). The ORR to ﬁrst line salvage chemotherapy was 50% in
TRFL pts versus 48% in RR-DLBCL pts (P  .79 -square). 50%
of TRFL and 45% of RR-DLBCL pts were able to proceed to
ASCT after all salvage chemotherapy and PBSC mobilization (P
.53, -square). For chemosensitive pts who underwent ASCT, the
2 year OS was similar (36% TRFL, 53% RR-DLBCL, P  .15)
while the 2 year PFS was inferior for TRFL (20% TRFL, 36%
RR-DLBCL, P  .04), with a similar median follow-up in both
groups (TRFL: 2 years, RR-DL 1.8 years). Conclusions: Pts with
TRFL were more likely to have advanced stage disease and were
more pre-treated prior to salvage therapy. The ORR to salvage
chemotherapy was similar but TRFL pts had an inferior PFS
(though not OS) post-ASCT. Studies should focus on developing
prognostic models to risk stratify TRFL, and novel therapies
should be considered.
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PROGNOSTIC FACTORS FOR SURVIVAL OF PATIENTS WITH NON-
HODGKIN’S LYMPHOMA (NHL) AFTER AUTOLOGOUS PERIPHERAL
STEM CELL TRANSPLANTATION (APSCT)—SINGLE CENTER EXPERI-
ENCE
Faber, E.1, Vondrakova, J.1, Zapletalova, J.2, Skoumalova, I.1,
Maresova, I.1, Raida, L.1, Papajik, T.1, Indrak, K.1 1. Department of
Hemato-Oncology, University Hospital, Olomouc, Czech Republic; 2.
Institute for Biophysics and Statistics, University Hospital, Olomouc,
Czech Republic.
Several prognostic factors had been previously reported to be
associated with overall and progression-free survival of patients
with NHL after APSCT. We present a retrospective single center
analysis with special attention to the markers that reﬂect the ac-
tivity of disease at the time of transplantation. 122 patients with
NHL indicated for APSCT for high-risk features at diagnosis
partial response to ﬁrst line treatment and/or relapse were included
in the study. There were 66 women and 56 men at median age 45.5
years (range 19–66). Forty-seven patients were with diagnosis of
diffuse-large cell lymphoma, 34 with follicular lymphoma, 15 with
mantle cell lymphoma, and 26 patients had other lymphoma sub-
types. Patients were transplanted in years 1997–2004. In all cases,
BEAM was used for conditioning. Median follow-up of patients
was 27 months (range 3.0–93.9). Fifty (41%) patients relapsed and
35 (28.7%) died. Age, stage of disease, IPI, bone marrow and
extra-nodal involvement, presence of B symptoms and bulky dis-
ease at diagnosis, activity of disease and Karnofski index at the time
of transplantation, response to therapy and levels of serologic
markers (LDH, -2-microglobulin and thymidine kinase) at the
diagnosis and at the time of transplantation were included in
univariate and multivariate analysis. For relapse-free survival level
of LDH at transplantation was identiﬁed as signiﬁcant factor both
in univariate analysis and Cox regression model (RR  3.63; 95%
CI 1.02–12.88, P .046). On the other hand, levels of LDH and
thymidine kinase at diagnosis and levels of LDH, thymidine kinase
and -2-microglobulin together with Karnofski score at transplan-
tation and age were found predictive for overall survival in univar-
iate analysis. Multivariate Cox regression analysis identiﬁed levels
of -2-microglobulin at transplantation (RR  2.59; 95% CI 
1.06–6.37, P  .038) and LDH at transplantation (RR  1.08;
95% CI  1.02–1.15, P  .007) as independent prognostic factors.
We conclude that clinical assessment of disease activity at trans-
plantation was not sufﬁcient for estimation of prognosis in our
patients. Levels of serologic markers as LDH and -2-microglobu-
lin at transplantation were found more useful and signiﬁcantly
correlated with overall survival of our patients with NHL after
APSCT. Supported by grant MSM 6198959205.
345
TOTAL MARROW IRRADIATION AND PERIPHERAL BLOOD PROGENI-
TOR CELL RESCUE FOLLOWING HIGH-DOSE MELPHALAN AND PERIPH-
ERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH MULTI-
PLE MYELOMA
Somlo, G.1, Forman, S.1, Popplewell, L.1, Spielberger, R.2, Sahebi, F.2,
Parker, P.1, Schultheiss, T.1, Liu, A.1, Krishnan, A.1, Wong, J.1 1. City
of Hope National Medical Center, Duarte, CA; 2. Kaiser Permanente,
Los Angeles, CA.
Tandem high-dose therapy (THDT) followed by peripheral
blood progenitor cell reinfusion (PBPC) is associated with a pro-
jected 20% progression-free survival at 7 years after treatment for
Poster Session II
120
